AB 301

Drug Profile

AB 301

Alternative Names: AB-301; Pegylated human glucagon-like peptide-1 agonist/AB 101

Latest Information Update: 21 Nov 2015

Price : $50

At a glance

  • Originator AntriaBio
  • Class
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 17 Nov 2015 AntriaBio receives patent allowance for AB 301 in USA
  • 16 Sep 2015 Preclinical trials in Type-2 diabetes mellitus in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top